Skip to content

The effect of soy isoflavones in migraine

The effect of soy isoflavones supplementation on symptoms of headache and CGRP in women with migraine

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20121216011763N44
Enrollment
88
Registered
2020-02-27
Start date
2020-02-20
Completion date
Unknown
Last updated
2020-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

migraine. Migraine

Interventions

Intervention 1: Intervention group: Eat one soybean daily with food for eight weeks. Intervention 2: Control group: One placebo (50 mg of starch) daily with food for 8 weeks.

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Women from the age of 18 to menopause Diagnosis of migraine by a neurologist Willing to work with the project

Exclusion criteria

Exclusion criteria: With breast cancer and endometrial cancer Problem or risk of breast or endometrial cancer in a breast examination by a gynecologist Having a family history of endometrial and breast cancer OCP medication use

Design outcomes

Primary

MeasureTime frame
Migraine symptoms (severity, frequency, duration of migraine). Timepoint: At baseline and after eight weeks. Method of measurement: Questionnaire.;Serum levels of calcitonin-associated peptide (CGRP). Timepoint: At baseline and after eight weeks. Method of measurement: Laboratory analysis (blood test).

Secondary

MeasureTime frame
Depression, stress, anxiety. Timepoint: At baseline and after eight weeks. Method of measurement: DASS-21questionnaire.;Quality of Life in Migraine Patients. Timepoint: Quality of Life in Migraine Patients. Method of measurement: Migraine –Specific Quality of Life(MSQ)questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGholamreza Askari

Esfahan University of Medical Sciences

askari@mui.ac.ir+98 31 1792 2110

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026